Literature DB >> 12933506

On meta-analytic assessment of surrogate outcomes.

M H Gail1, R Pfeiffer, H C Van Houwelingen, R J Carroll.   

Abstract

We discuss the strengths and weaknesses of the meta-analytic approach to estimating the effect of a new treatment on a true clinical outcome measure, T, from the effect of treatment on a surrogate response, S. The meta-analytic approach (see Daniels and Hughes (1997) 16, 1965-1982) uses data from a series of previous studies of interventions similar to the new treatment. The data are used to estimate relationships between summary measures of treatment effects on T and S that can be used to infer the magnitude of the effect of the new treatment on T from its effects on S. We extend the class of models to cover a broad range of applications in which the parameters define features of the marginal distribution of (T, S). We present a new bootstrap procedure to allow for the variability in estimating the distribution that governs the between-study variation. Ignoring this variability can lead to confidence intervals that are much too narrow. The meta-analytic approach relies on quite different data and assumptions than procedures that depend, for example, on the conditional independence, at the individual level, of treatment and T, given S (see Prentice (1989) 8, 431-440). Meta-analytic calculations in this paper can be used to determine whether a new study, based only on S, will yield estimates of the treatment effect on T that are precise enough to be useful. Compared to direct measurement on T, the meta-analytic approach has a number of limitations, including likely serious loss of precision and difficulties in defining the class of previous studies to be used to predict the effects on T for a new intervention.

Year:  2000        PMID: 12933506     DOI: 10.1093/biostatistics/1.3.231

Source DB:  PubMed          Journal:  Biostatistics        ISSN: 1465-4644            Impact factor:   5.899


  33 in total

1.  Principal stratification in causal inference.

Authors:  Constantine E Frangakis; Donald B Rubin
Journal:  Biometrics       Date:  2002-03       Impact factor: 2.571

2.  A unified procedure for meta-analytic evaluation of surrogate end points in randomized clinical trials.

Authors:  James Y Dai; James P Hughes
Journal:  Biostatistics       Date:  2012-03-06       Impact factor: 5.899

3.  Predicting treatment effect from surrogate endpoints and historical trials: an extrapolation involving probabilities of a binary outcome or survival to a specific time.

Authors:  Stuart G Baker; Daniel J Sargent; Marc Buyse; Tomasz Burzykowski
Journal:  Biometrics       Date:  2011-08-13       Impact factor: 2.571

4.  The intermediate endpoint effect in logistic and probit regression.

Authors:  D P MacKinnon; C M Lockwood; C H Brown; W Wang; J M Hoffman
Journal:  Clin Trials       Date:  2007       Impact factor: 2.486

5.  Considerations for development of surrogate endpoints for antifracture efficacy of new treatments in osteoporosis: a perspective.

Authors:  Mary L Bouxsein; Pierre D Delmas
Journal:  J Bone Miner Res       Date:  2008-08       Impact factor: 6.741

6.  Multivariate meta-analysis with an increasing number of parameters.

Authors:  Simina M Boca; Ruth M Pfeiffer; Joshua N Sampson
Journal:  Biom J       Date:  2017-02-14       Impact factor: 2.207

7.  Pathologic complete response and disease-free survival are not surrogate endpoints for 5-year survival in rectal cancer: an analysis of 22 randomized trials.

Authors:  Fausto Petrelli; Karen Borgonovo; Mary Cabiddu; Mara Ghilardi; Veronica Lonati; Sandro Barni
Journal:  J Gastrointest Oncol       Date:  2017-02

8.  Surrogate endpoint analysis: an exercise in extrapolation.

Authors:  Stuart G Baker; Barnett S Kramer
Journal:  J Natl Cancer Inst       Date:  2012-12-21       Impact factor: 13.506

9.  Predicting treatment effects using biomarker data in a meta-analysis of clinical trials.

Authors:  Y Li; J M G Taylor
Journal:  Stat Med       Date:  2010-08-15       Impact factor: 2.373

10.  Meta-analysis for surrogacy: accelerated failure time models and semicompeting risks modeling.

Authors:  Debashis Ghosh; Jeremy M G Taylor; Daniel J Sargent
Journal:  Biometrics       Date:  2011-06-13       Impact factor: 2.571

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.